Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Satisfying Sexual Events (SSE): In premenopausal women, flibanserin 100 mg increased the mean number of SSE per month compared to placebo (Mean Difference, MD 0.69, 95% Confidence Interval, CI [0.39, 0.99]).
• Sexual Desire and Function Scores: Flibanserin significantly improved the eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (MD 0.30, 95% CI [0.29, 0.31]), and total FSFI score (MD 2.51, 95% CI [1.47, 3.55]) compared to placebo.
• Sexual Distress and Overall Improvement: Reductions were observed in Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD -0.30, 95% CI [-0.31, -0.29]) and FSDS-R total score (MD -3.30, 95% CI [-3.37, -3.23]), with increased odds of improvement in Patient's Global Impression of Improvement (PGI-I) score (OR 1.93, 95% CI [1.58, 2.36], P < .00001).
• Common Adverse Events: Flibanserin use was associated with increased risks of mild adverse events, including dizziness, fatigue, nausea, somnolence, and insomnia, compared to placebo, with no significant differences in the incidence of serious or severe adverse events between groups.
• There is no population type or subgroup information available in the reviewed studies.